{"id":763177,"date":"2023-06-12T18:27:04","date_gmt":"2023-06-12T22:27:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/"},"modified":"2023-06-12T18:27:04","modified_gmt":"2023-06-12T22:27:04","slug":"iterum-therapeutics-to-present-data-at-asm-microbe-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/","title":{"rendered":"Iterum Therapeutics to Present Data at ASM Microbe 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">DUBLIN, Ireland and CHICAGO, June  12, 2023  (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference.<\/p>\n<p align=\"justify\">The hybrid conference will be held from June 15-19 at the George R. Brown Convention Center in Houston, TX.<\/p>\n<p align=\"justify\">Data to be presented include:<\/p>\n<p align=\"justify\">\n        <strong>Presentation title: <\/strong>\u03b2-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Uncomplicated Urinary Tract Infection<\/p>\n<p align=\"justify\">\n        <strong>Presentation type\/category: <\/strong>P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; \u03b2-lactamases (AAR-Friday-410)<br \/><strong>Presenter: <\/strong>Steven I. Aronin, MD<br \/><strong>Time\/location: <\/strong>June 16, 2023, 10:00 a.m. \u2013 5:00 p.m. CDT; Exhibit and Poster Hall B, C, D<\/p>\n<p align=\"justify\">\n        <strong>Presentation title: <\/strong>\u03b2-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infection<\/p>\n<p align=\"justify\">\n        <strong>Presentation type\/category:<\/strong> P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; \u03b2-lactamases (AAR-Friday-417)<br \/><strong>Presenter: <\/strong>Sailaja Puttagunta, MD<br \/><strong>Time\/location: <\/strong>June 16, 2023, 10:00 a.m. \u2013 5:00 p.m. CDT; Exhibit and Poster Hall B, C, D<\/p>\n<p align=\"justify\">\n        <strong>Presentation title: <\/strong>\u03b2-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Complicated Intraabdominal Infection <\/p>\n<p align=\"justify\">\n        <strong>Presentation type\/category: <\/strong>P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; \u03b2-lactamases (AAR-Friday-401)<br \/><strong>Presenter: <\/strong>Sailaja Puttagunta, MD<br \/><strong>Time\/location: <\/strong>June 16, 2023, 10:00 a.m. \u2013 5:00 p.m. CDT; Exhibit and Poster Hall B, C, D<\/p>\n<p align=\"justify\">These Posters will be made available on the Company\u2019s website on the \u201c<em>Publications: Posters &amp; Presentations<\/em>\u201d page under the \u201cOur Science\u201d tab once the conference ends.<\/p>\n<p align=\"justify\">\n        <strong>About Iterum Therapeutics plc<\/strong>\n      <\/p>\n<p align=\"justify\">Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent <em>in vitro<\/em> activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Judy Matthews<br \/>Chief Financial Officer <br \/>312-778-6073<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m2JfJslDQyOAC2e0qekeOhj30h5djwm5xBZS92Q1bG1A9ImN7cMXe8Zdi0KpDN_v4ccBqjV6tUv3pVWCrhikpQ==\" rel=\"nofollow noopener\" target=\"_blank\">IR@iterumtx.com<\/a><\/u>\u00a0<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTgzNDViNDEtYTQxOC00ZGM0LTlhN2MtN2U4NWViYjI2MmRlLTEyMjA2MDc=\/tiny\/Iterum-Therapeutics-PLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference. The hybrid conference will be held from June 15-19 at the George R. Brown Convention Center in Houston, TX. Data to be presented include: Presentation title: \u03b2-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Uncomplicated Urinary Tract Infection Presentation type\/category: P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; \u03b2-lactamases (AAR-Friday-410)Presenter: Steven I. Aronin, MDTime\/location: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Iterum Therapeutics to Present Data at ASM Microbe 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-763177","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iterum Therapeutics to Present Data at ASM Microbe 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iterum Therapeutics to Present Data at ASM Microbe 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference. The hybrid conference will be held from June 15-19 at the George R. Brown Convention Center in Houston, TX. Data to be presented include: Presentation title: \u03b2-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Uncomplicated Urinary Tract Infection Presentation type\/category: P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; \u03b2-lactamases (AAR-Friday-410)Presenter: Steven I. Aronin, MDTime\/location: &hellip; Continue reading &quot;Iterum Therapeutics to Present Data at ASM Microbe 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-12T22:27:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iterum Therapeutics to Present Data at ASM Microbe 2023\",\"datePublished\":\"2023-06-12T22:27:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/\"},\"wordCount\":401,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/\",\"name\":\"Iterum Therapeutics to Present Data at ASM Microbe 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=\",\"datePublished\":\"2023-06-12T22:27:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iterum Therapeutics to Present Data at ASM Microbe 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iterum Therapeutics to Present Data at ASM Microbe 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/","og_locale":"en_US","og_type":"article","og_title":"Iterum Therapeutics to Present Data at ASM Microbe 2023 - Market Newsdesk","og_description":"DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) &#8212; Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference. The hybrid conference will be held from June 15-19 at the George R. Brown Convention Center in Houston, TX. Data to be presented include: Presentation title: \u03b2-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Uncomplicated Urinary Tract Infection Presentation type\/category: P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; \u03b2-lactamases (AAR-Friday-410)Presenter: Steven I. Aronin, MDTime\/location: &hellip; Continue reading \"Iterum Therapeutics to Present Data at ASM Microbe 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-12T22:27:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iterum Therapeutics to Present Data at ASM Microbe 2023","datePublished":"2023-06-12T22:27:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/"},"wordCount":401,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/","name":"Iterum Therapeutics to Present Data at ASM Microbe 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=","datePublished":"2023-06-12T22:27:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1Njg5MiM1NjQzNzM3IzIyMDkwNTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iterum-therapeutics-to-present-data-at-asm-microbe-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iterum Therapeutics to Present Data at ASM Microbe 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/763177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=763177"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/763177\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=763177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=763177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=763177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}